These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 14680295)

  • 1. Immunotherapy of HPV 16-associated tumours with tumour cell line/dendritic cell line (TC-1/DC2.4) hybrid vaccines.
    Símová J; Bieblová J; Jandlová T; Bubeník J
    Folia Biol (Praha); 2003; 49(5):203-6. PubMed ID: 14680295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic efficacy of vaccines generated by fusion of dendritic cells and HPV16-associated tumour cells.
    Símová J; Bubeník J; Bieblová J; Indrová M; Jandlová T
    Folia Biol (Praha); 2005; 51(1):19-24. PubMed ID: 15783088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-inhibitory effects of dendritic cells administered at the site of HPV 16-induced neoplasms.
    Mendoza L; Bubeník J; Símová J; Korb J; Bieblová J; Vonka V; Indrová M; Mikysková R; Jandlová T
    Folia Biol (Praha); 2002; 48(3):114-9. PubMed ID: 12118725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
    Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
    Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
    Chandy AG; Nurkkala M; Josefsson A; Eriksson K
    Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours.
    Mendoza L; Bubeník J; Símová J; Jandlová T; Vonka V; Mikysková R
    Int J Oncol; 2003 Jul; 23(1):243-7. PubMed ID: 12792800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas.
    Ni HT; Spellman SR; Jean WC; Hall WA; Low WC
    J Neurooncol; 2001 Jan; 51(1):1-9. PubMed ID: 11349874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
    Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
    Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16.
    Bubeník J; Mikysková R; Vonka V; Mendoza L; Símová J; Smahel M; Indrová M
    Vaccine; 2003 Feb; 21(9-10):891-6. PubMed ID: 12547599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.
    Indrová M; Bubeník J; Símová J; Vonka V; Nemecková S; Mendoza L; Reinis M
    Int J Mol Med; 2001 Jan; 7(1):97-100. PubMed ID: 11115616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols.
    Lindner M; Schirrmacher V
    Eur J Clin Invest; 2002 Mar; 32(3):207-17. PubMed ID: 11895473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
    Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V
    Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic immune response induced by electrofusion of dendritic and tumor cells.
    Tanaka H; Shimizu K; Hayashi T; Shu S
    Cell Immunol; 2002 Nov; 220(1):1-12. PubMed ID: 12718934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity.
    Takeda A; Homma S; Okamoto T; Kufe D; Ohno T
    Eur J Clin Invest; 2003 Oct; 33(10):897-904. PubMed ID: 14511362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.